Europe Neurological Disorder Drugs Market

Neurological Disorder Drugs Market (Disorder - Epilepsy, Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, and Cerebrovascular Disease; Drug Type - Anticholinergic, Antiepileptic, Antipsychotic, Analgesics, Hypnotic & Sedative, Antihypertensive, and Anticoagulants; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and eCommerce) - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • Rep Id : TMRGL17567
  • Published On : Dec 2016
  • No. of Pages : 224
  • Category : Pharmaceutical

Section 1 Preface 
1.1 Report Scope and Market Segmentation 
1.2 Assumptions and Acronyms Used
1.3 Research Methodology

Section 2 Market Overview
2.1 Executive Summary
2.2 Market Snapshot

Section 3 Market Dynamics
3.1 Drivers and Restraints Snapshot Analysis
3.2 Drivers
      3.2.1 Aging population leading to increase neurological disorders
      3.2.2 Increasing Therapeutic Treatments
      3.2.3 Rise in interventions by government bodies
      3.2.4 Rising Research & Development Programmes
      3.2.5 Spending on neurological drugs to grow in developing countries
      3.2.6 Growing awareness among people
3.3 Restraints
      3.3.1 High treatment cost
      3.3.2 Stringent regulations
3.4 Opportunities
      3.5.1 Technological Advancement and Innovation
      3.5.2 Significant Scope in Emerging Markets

Section 4 Market Overview
4.1 Europe Neurological Disorder Drugs Market Analysis and Forecasts, Market Revenue Projections (US$ Mn)
4.2 Disease description and epidemiology
      4.2.1 Muscle Dystrophy
      4.2.2 Multiple Sclerosis
      4.2.3 Parkinson Disease
      4.2.4 Amputees
4.3 Disease Frequency by Country
4.4 Future Outlook
4.5 Target population by Age Group
4.6 Alzheimer Disease - Prevalence Rate
4.7 Living Conditions
4.8 Neurological Disorder Drugs Market Outlook

Section 5 Europe Neurological Disorder Drugs Market Analysis, by Disorder
5.1 Introduction
5.2 Europe Neurological Disorder Drugs Market Value Share and Attractiveness Analysis, by Disorder
5.3 Europe Neurological Disorder Drugs Market Forecast, by Disorder
      5.3.1 Epilepsy
      5.3.2 Alzheimer’s Disease
      5.3.3 Parkinson Disease
      5.3.4 Multiple Sclerosis
      5.3.5 Cerebrovascular Disease
      5.3.6 Others

Section 6 Europe Neurological Disorder Drugs Market Analysis, by Drug Type
6.1 Introduction
6.2 Europe Neurological Disorder Drugs Market Value Share and Attractiveness Analysis, by Drug Type
6.3 Europe Neurological Disorder Drugs Market Forecast, by Drug Type
      6.3.1 Anticholinergic
      6.3.2 Antiepileptic
      6.3.3 Antipsychotic
      6.3.4 Analgesics
      6.3.5 Hypnotic & Sedative
      6.3.6 Antihypertensive
      6.3.7 Anticoagulants
      6.3.8 Others

Section 7 Europe Neurological Disorder Drugs Market Analysis, by Distribution Channel
7.1 Introduction
7.2 Europe Neurological Disorder Drugs Market Value Share and Attractiveness Analysis, by Distribution Channel
7.3 Europe Neurological Disorder Drugs Market Forecast, by Distribution Channel
      7.3.1 Hospital Pharmacy
      7.3.2 Retail Pharmacy
      7.3.3 eCommerce

Section 8 Europe Neurological Disorder Drugs Market Analysis By Country
8.1 Neurological Disorder Drugs Market Forecast, By Country

Section 9 Germany Neurological Disorder Drugs Market Analysis
9.1 Germany Neurological Disorder Drugs Market Overview
9.2 Germany Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
9.3 Germany Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
9.4 Disease description and epidemiology
      9.4.1 Muscular Dystrophy
      9.4.2 Multiple Sclerosis
      9.4.3 Parkinson’s Disease
      9.4.4 Amputees
9.5 Disease Frequency by Country
9.6 Target population by Age Group
9.7 Alzheimer's Disease – Prevalence Rate
9.8 Living Conditions

Section 10 UK Neurological Disorder Drugs Market Analysis
10.1 UK Neurological Disorder Drugs Market Overview
10.2 UK Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
10.3 UK Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
10.4 Disease description and epidemiology
      10.4.1 Muscular Dystrophy
      10.4.2 Multiple Sclerosis
      10.4.3 Parkinson’s Disease
      10.4.4 Amputees
      10.4.5 Disease Cost
10.5 Target population by Age Group
10.6 Alzheimer's Disease – Prevalence Rate
10.7 Living Conditions

Section 11 France Neurological Disorder Drugs Market Analysis
11.1 France Neurological Disorder Drugs Market Overview
11.2 France Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
11.3 France Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
11.4 Disease description and epidemiology
      11.4.1 Muscular Dystrophy
      11.4.2 Multiple Sclerosis
      11.4.3 Factors Associated with Increased Risk for Multiple Sclerosis
      11.4.4 Parkinson’s Disease
      11.4.5 Amputees
11.5 Disease Cost
11.6 Target population by Age Group
11.7 Alzheimer's Disease – Prevalence Rate
11.8 Living Conditions

Section 12 Italy Neurological Disorder Drugs Market Analysis
12.1 Italy Neurological Disorder Drugs Market Overview
12.2 Italy Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
12.3 Italy Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
12.4 Disease description and epidemiology
      12.4.1 Muscular Dystrophy
      12.4.2 Multiple Sclerosis
      12.4.3 Parkinson’s Disease
      12.4.4 Amputees
12.5 Disease Frequency
12.6 Target population by Age Group
12.7 Alzheimer's Disease – Prevalence Rate
12.8 Disability – Targeted Age Group 
12.9 Living Conditions

Section 13 Spain Neurological Disorder Drugs Market Analysis
13.1 Spain Neurological Disorder Drugs Market Overview
13.2 Spain Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
13.3 Spain Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
13.4 Disease description and epidemiology
      13.4.1 Muscular Dystrophy
      13.4.2 Multiple Sclerosis
      13.4.3 Parkinson’s Disease
      13.4.4 Amputees
13.5 Target population by Age Group
13.6 Alzheimer's Disease – Targeted Age Group
13.7 Living Conditions

Section 14 Russia Neurological Disorder Drugs Market Analysis
14.1 Russia Neurological Disorder Drugs Market Overview
14.2 Russia Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
14.3 Russia Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
14.4 Disease description and epidemiology
      14.4.1 Muscular Dystrophy
      14.4.2 Multiple Sclerosis
      14.4.3 Parkinson’s Disease
      14.4.4 Amputees
14.5 Target population by Age Group
14.6 Living Conditions

Section 15 Netherlands Neurological Disorder Drugs Market Analysis
15.1 Netherlands Neurological Disorder Drugs Market Overview
15.2 Netherlands Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
15.3 Netherlands Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
15.4 Disease description and epidemiology
      15.4.1 Muscular Dystrophy
      15.4.2 Multiple Sclerosis
      15.4.3 Parkinson’s Disease
      15.4.4 Amputees
15.5 Disease Cost
15.6 Target population by Age Group
15.7 Alzheimer's Disease – Prevalence Rate
15.8 Living Conditions

Section 16 Switzerland Neurological Disorder Drugs Market Analysis
16.1 Switzerland Neurological Disorder Drugs Market Overview
16.2 Switzerland Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
16.3 Switzerland Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
16.4 Disease description and epidemiology
      16.4.1 Muscular Dystrophy
      16.4.2 Multiple Sclerosis
      16.4.3 Parkinson’s Disease
      16.4.4 Amputees
16.5 Disease Cost
16.6 Target population by Age Group
16.7 Alzheimer's Disease – Prevalence Rate
16.8 Living Conditions

Section 17 Poland Neurological Disorder Drugs Market Analysis
17.1 Poland Neurological Disorder Drugs Market Overview
17.2 Poland Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
17.3 Poland Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
17.4 Disease description and epidemiology
      17.4.1 Muscular Dystrophy
      17.4.2 Multiple Sclerosis
      17.4.3 Parkinson’s Disease
      17.4.4 Amputees
17.5 Target population by Age Group
17.6 Alzheimer's Disease – Targeted Age Group
17.7 Alzheimer's Disease – Prevalence Rate
17.8 Living Conditions

Section 18 Rest of Europe Neurological Disorder Drugs Market Analysis
18.1 Rest of Europe Neurological Disorder Drugs Market Overview
18.2 Rest of Europe Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
18.3 Rest of Europe Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
18.4 Disease description and epidemiology
      18.4.1 Muscular Dystrophy
      18.4.2 Multiple Sclerosis
      18.4.3 Parkinson’s Disease
      18.4.4 Amputees
18.5 Alzheimer's Disease – Prevalence Rate
18.6 Living Conditions

Section 19 Company Profiles
19.1 Neurological Disorder Drugs Market Share Analysis, by Company (2015)
19.2 Company profiles
      19.2.1 Novartis AG
               19.2.1.1. Company Overview
               19.2.1.2. Business Overview
               19.2.1.3. Financial Overview
               19.2.1.4. SWOT Analysis
               19.2.1.5. Strategic Overview
      19.2.2 GlaxoSmithKline plc
               19.2.2.1. Company Overview
               19.2.2.2. Business Overview
               19.2.2.3. Financial Overview
               19.2.2.4. SWOT Analysis
               19.2.2.5. Strategic Overview      
      19.2.3 Merck & Co.
               19.2.3.1. Company Overview
               19.2.3.2. Business Overview
               19.2.3.3. Financial Overview
               19.2.3.4. SWOT Analysis
               19.2.3.5. Strategic Overview
      19.2.4 Bayer AG
               19.2.4.1. Company Overview
               19.2.4.2. Business Overview
               19.2.4.3. Financial Overview
               19.2.4.4. SWOT Analysis
               19.2.4.5. Strategic Overview
      19.2.5 AstraZeneca
               19.2.5.1. Company Overview
               19.2.5.2. Business Overview
               19.2.5.3. Financial Overview
               19.2.5.4. SWOT Analysis
               19.2.5.5. Strategic Overview
      19.2.6 Boehringer Ingelheim GmbH
               19.2.6.1. Company Overview
               19.2.6.2. Business Overview
               19.2.6.3. Financial Overview
               19.2.6.4. SWOT Analysis
               19.2.6.5. Strategic Overview
      19.2.7 Teva Pharmaceutical Industries Ltd.
               19.2.7.1. Company Overview
               19.2.7.2. Business Overview
               19.2.7.3. Financial Overview
               19.2.7.4. SWOT Analysis
               19.2.7.5. Strategic Overview
      19.2.8 F. Hoffmann-La Roche Ltd.
               19.2.8.1. Company Overview
               19.2.8.2. Business Overview
               19.2.8.3. Financial Overview
               19.2.8.4. SWOT Analysis
               19.2.8.5. Strategic Overview

List of Tables

Table 01: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, by Disorder, 2014–2024 
Table 02: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2014–2024 
Table 03: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024 
Table 04: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024

List of Figures

Figure 01: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2015–2024 
Figure 02: Europe Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 03: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2015
Figure 04: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 05: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 06: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 07: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 08: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 09: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 10: Europe Neurological Disorder Drugs Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 11: Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Type
Figure 12: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 13: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 14: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 15: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 16: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 17: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 18: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 19: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 20: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 21: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 22: Europe Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 23: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution channel, 2015
Figure 24: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacy, 2014–2024 
Figure 25: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacy, 2014–2024 
Figure 26: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by E-commerce, 2014–2024 
Figure 27: Europe Neurological Disorder Drugs Market Value Share Analysis, by Country Type, 2016 and 2024 
Figure 28: Neurological Disorder Drugs Market Attractiveness Analysis, by Region Type
Figure 29: Germany Neurological Disorder Drugs Market Size
Figure 30: Germany Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015–2024
Figure 31: Germany Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 32: Germany Market Value Share Analysis, by Drug Type, 2016 and 2024
Figure 33: Germany Market Value Share Analysis, by Distribution channel, 2016 and 2024 
Figure 34: U.K. Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024 
Figure 35: U.K. Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015–2024
Figure 36: U.K. Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 37: U.K. Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 38: U.K. Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 39: France Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024 
Figure 40: France Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015–2024
Figure 41: France Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 42: France Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 43: France Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 44: Italy Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024 
Figure 45: Italy Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015–2024
Figure 46: Italy Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 47: Italy Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 48: Italy Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 49: Spain Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024 
Figure 50: Spain Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015–2024
Figure 51: Spain Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 52: Spain Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 53: Spain Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 54: Russia Neurological Disorder Drugs Market Size
Figure 55: Russia Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015–2024
Figure 56: Russia Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 57: Russia Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 58: Russia Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 59: Netherlands Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 60: Netherlands Neurological Disorder Drugs Market Size Y-o-Y Growth Projections (%), 2015–2024
Figure 61: Netherlands Market Value Share Analysis, by Disorder, 2016 and 2024
Figure 62: Netherlands Market Value Share Analysis, by Drug Type, 2016 and 2024
Figure 63: Netherlands Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 64: Switzerland Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 65: Switzerland Neurological Disorder Drugs Market Size Y-o-Y Growth Projections (%), 2015–2024
Figure 66: Switzerland Market Value Share Analysis, by Disorder, 2016 and 2024
Figure 67: Switzerland Market Value Share Analysis, by Drug Type, 2016 and 2024
Figure 68: Switzerland Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 69: Poland Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024 
Figure 70: Poland Neurological Disorder Drugs Market Size Y-o-Y Growth Projections (%), 2015–2024
Figure 71: Poland Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 72: Poland Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 73: Poland Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 74: Rest of Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024 
Figure 75: Rest of Europe Neurological Disorder Drugs Market Size Y-o-Y Growth Projections (%), 2015–2024
Figure 76: Rest of Europe Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 77: Rest of Europe Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 78: Rest of Europe Market Value Share Analysis, by Distribution Channel, 2016 and 2024

.